alpha-En (ALPE) 10-Q 17 Jan 17 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Jan. 05, 2017
Document And Entity Information
Entity Registrant Name	alpha-En Corp
Entity Central Index Key	1,023,298
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		32,892,089
Trading Symbol	ALPE
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets
Cash	$ 693	$ 730
Prepaid expenses	340	301
Due from related party		61
Total current assets	1,033	1,092
Property and equipment, net	36	2
Total assets	1,069	1,094
Current liabilities
Accounts payable and accrued expenses	319	341
Advances from related parties	92	62
Total current liabilities	411	403
Total liabilities	411	403
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Preferred stock par value $0.01: 2,000,000 shares authorized; none issued or outstanding
Common stock	334	322
Additional paid-in capital	11,692	10,705
Treasury stock at cost: 714,750 shares as of March 31, 2016 and December 31, 2015	(69)	(69)
Accumulated deficit	(11,134)	(10,169)
Shareholders' equity attributed to alpha-En Corporation stockholders	823	789
Non-controlling interest	(165)	(98)
Total stockholders' equity	658	691
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,069	1,094
Common Class B [Member]
Stockholders' equity:
Common stock

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Preferred stock, par or stated value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares, issued	33,423,026	32,235,525
Common stock, shares, outstanding	33,423,026	32,235,525
Treasury stock, shares	714,750	714,750
Common Class B [Member]
Common stock, par or stated value per share
Common stock, shares authorized	1,000,000	1,000,000
Common stock, shares, issued
Common stock, shares, outstanding

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating expenses
General and administrative	$ 583	$ 28
Legal and professional fees	49	7
Research and development	394	28
Total operating expenses	1,026	63
Net loss	(1,026)	(63)
Less: net loss attributable to non-controlling interest	(61)	(1)
Net loss attributable to alpha-En Corporation	$ (965)	$ (62)
Net loss per share attributable to alpha-En Corporation common stockholders
Basic and diluted	$ (0.03)	$ 0
Weighted average shares outstanding:
Basic and diluted	32,448,987	30,285,525

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2014	$ 286	$ 10,741	$ (69)	$ (10,169)	$ (98)	$ 691
Balance, Shares at Dec. 31, 2014	28,649,497		714,750
Correction to outstanding shares	$ 36	(36)
Correction to outstanding shares, Shares	3,586,028
Balance at Dec. 31, 2015	$ 322	10,705	$ (69)	(10,169)	(98)	691
Balance, Shares at Dec. 31, 2015	32,235,525		714,750
Stock based compensation		627				627
Issuance of restricted stock to employee	$ 7	(7)
Issuance of restricted stock to employee, Shares	650,000
Options exercised for cash	$ (1)	(10)				11
Options exercised for cash, Shares	100,000
Issuance of common stock and warrants in a private placement	$ 4	276				280
Issuance of common stock and warrants in a private placement, Shares	437,501
Issuance of subsidiary common stock for service		81			(6)	(75)
Net loss				(965)	(61)	(1,026)
Balance at Mar. 31, 2016	$ 334	$ 11,692	$ (69)	$ (11,134)	$ (165)	$ 658
Balance, Shares at Mar. 31, 2016	33,423,026		714,750

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (1,026)	$ (63)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1
Stock-based compensation	627	35
Issuance of subsidiary common stock for service	75
Changes in operating assets and liabilities of business:
Prepaid expenses	(39)	(69)
Due from related parties	61
Accounts payable and accrued expenses	(22)	2
Net cash used in operating activities	(323)	(95)
Cash flows from investing activities
Purchase of fixed assets	(35)	(2)
Net cash used in investing activities	(35)	(2)
Cash flows from financing activities
Options exercised for cash	11
Proceeds from issuance of common stock and warrants in private placement	280
Advances from related parties	50
Repayments of advances from related parties	(20)
Net cash provided by financing activities	321
Net decrease in cash	(37)	(97)
Cash at beginning of period	730	103
Cash at end of period	$ 693	$ 6

Organization and Operations

Organization and Operations	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Operations	Note 1 - Organization and Operations alpha-En Corporation (together with its subsidiaries, the “Company”) was incorporated in Delaware on March 7, 1997. On February 25, 2009, alpha-En Corporation was granted a license for an exclusive, worldwide, transferable, perpetual license to use certain proprietary technology for the processing of lithium for use in batteries. After much effort, it was determined the process was not commercially feasible and efforts surrounding this technology were abandoned in 2011. The Company has settled an amendment and release related to this license. (See Note 7) During 2011 and 2012, alpha-En Corporation devoted its resources to developing proprietary technology to produce highly pure lithium metal. In 2013, alpha-En Corporation invented a new process for the production of highly pure lithium metal and associated products at room temperature and subsequently broadened its focus to develop products and processes derived from its new core proprietary technology, including battery components and compounds of lithium. During the period from 2013 to the present, alpha-En Corporation has been exclusively focused on developing its own technology for the production of highly pure lithium metal, from the bench scale through multiple demonstrations, with the end goal of commercialization. During this time, alpha-En Corporation has also been pursuing strategic partnerships both commercially and with research institutions. Formation of Majority-Owned Subsidiary In September 2014, alpha-En Corporation formed Clean Lithium Corporation (“CLC”) under the laws of New York State as a wholly owned subsidiary with a nominal share capital of $100,000. Following the sale of CLC’s shares, the ownership is as follows: Stockholder Shares Percentage alpha-En Corporation 9,095,000 90.95 % Non-controlling interests 905,000 9.05 % Total: 10,000,000 100.00 %

Going Concern and Liquidity

Going Concern and Liquidity	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Liquidity	Note 2 – Going Concern and Liquidity The Company has elected to adopt early application of Accounting Standards Update No. 2014-15, “Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”) The Company’s condensed consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the condensed consolidated financial statements, the Company had an accumulated deficit of approximately $11.1 million and $10.2 million at March 31, 2016 and December 31, 2015, respectively. A net loss of approximately $965,000 and $62,000, and approximately $323,000 and $95,000 net cash used in operating activities for the three months ended March 31, 2016 and 2015, respectively. The Company is attempting to further develop the intellectual property associated with its technology; broaden its patent portfolio; scale up our production of various products; and begin generating revenue; however, the Company’s cash position is not sufficient to support its daily operations. While the Company believes in the viability of its strategy and in its ability to raise additional funds by way of a public or private offering, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional funds by way of a public or private offering and its ability to further develop its technology and generate sufficient revenue. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant and Critical Accoun

Significant and Critical Accounting Policies and Practices	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Significant and Critical Accounting Policies and Practices	Note 3 - Significant and Critical Accounting Policies and Practices Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net income (loss) attributable to non-controlling interests in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K filed on October 20, 2016. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated. Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Fair Value Measurements Accounts Payable and Accrued Expenses. Cash As of March 31, 2016 and December 31, 2015, substantially all of the Company’s cash was held at major financial institutions and the balance at certain accounts may exceed the maximum amount insured by the Federal Deposit Insurance Corporation. However, the Company has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such accounts. Property and Equipment Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset, generally three years. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. There was no impairment of long lived assets during the quarter ended March 31, 2016. Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed. Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit. Loss Per Share Basic loss per share of common stock is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at March 31, 2016 and 2015 are as follows: As of March 31, 2016 2015 Warrants to purchase common stock 2,025,000 150,000 Options to purchase common stock 4,170,000 2,670,000 Total 6,195,000 2,820,000 Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment The components of property and equipment as of March 31, 2016 and December 31, 2015, at cost are (dollars in thousands): ($ in thousands) Useful Life (Years) March 31, 2016 December 31, 2015 Lab equipment 3 2 2 Office furniture and equipment 3 4 - Leasehold improvement 31 - Gross property and equipment 37 2 Less: Accumulated depreciation (1 ) - Property and equipment, net $ 36 $ 2 The Company’s depreciation expense for the three months ended March 31, 2016 and 2015 was $1,000 and $0, respectively.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Note 5 – Related Party Transactions Advances from Stockholders From time to time, stockholders of the Company advance funds to the Company for working capital purposes. Those advances are unsecured, non-interest bearing and due on demand. As of March 31, 2016 and December 31, 2015, the outstanding amount of the advances from related parties was approximately $92,000 and $62,000, respectively. During the three months ended March 31, 2016, advances from related parties was $50,000 and the Company repaid $20,000 to related parties. Free Office Space The Company has been provided office space by its Executive Chairman of the Board at no cost. The management determined that such cost is nominal and did not recognize the rent expense in its financial statements. Restricted Stock Grant to Chief Executive Officer and Associated Withholding Payments During three months ended March 31, 2016, Steven M. Fludder, Chief Executive Officer, paid the Company a withholding tax obligation of $198,000 related to the grant of restricted stock in 2015.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity	Note 6 – Stockholders’ Equity Adjustment to Outstanding Shares and Options In the consolidated financial statements for the years ended December 31, 2015 and 2014 filed with the SEC, the Company incorrectly excluded 3.6 million shares of common stock and 150,000 non-employee stock options, of which 75,000 were vested, in the calculation of basic and diluted earnings per share, weighted average and number of common shares outstanding. Given the net loss in 2014 and 2015, the excluded stock options had no impact earnings per share as their effect, if included, would have been anti-dilutive. In addition, the exclusion of 3.6 million shares of common stock also did not have a material effect on earnings per share. As a result, net loss per common share outstanding, basic and diluted, weighted average and the number of common shares outstanding were misstated by an amount that the Company has determined to be immaterial. The exclusion of such shares does not affect total stockholders’ equity or net loss. The following table provides a comparison between the previously filed numbers and the numbers after the correction as of December, 31(in thousands, except share): Previous Filings After Correction of Error 2015 2014 2015 2014 Total shares outstanding 28,649,497 26,699,497 32,235,525 30,285,525 Common stock $ 286 $ 267 $ 322 $ 303 Additional paid-in capital $ 10,741 $ 8,130 $ 10,705 $ 8,094 The following table provides a comparison between the previously filed numbers and the numbers after the correction for the years ended December, 31: Previous Filings After Correction of Error 2015 2014 2015 2014 Net loss $ 1,792,000 $ 47,000 $ 1,792,000 $ 47,000 Net loss per share $ (0.07 ) $ (0.00 ) $ (0.06 ) $ (0.00 ) Weighted-average shares 27,263,059 26,394,554 30,849,087 29,980,582 In accordance with the SEC’s Staff Accounting Bulletin Nos. 99 (“SAB 99”), the Company evaluated this error and, based on an analysis of quantitative and qualitative factors, determined that the error was immaterial to the prior reporting periods affected. Therefore, as permitted by SAB 99, the Company corrected, in the current filing, the calculation of basic earnings per share and weighted average number of common shares outstanding as of December 31, 2015. Common Stock During three months ended March 31, 2016, the Company entered into six private placement offerings with six investors and issued 437,501 shares of its common stock and warrants to purchase 175,000 shares of common stock for $280,000. The warrants have a 5-year term and an exercise price of $0.97. The Company also issued 75,000 shares of its subsidiary, CLC, to a consultant for the service provided, and the shares were valued at $1.00 per share. As of March 31, 2016, there were warrants to purchase 2,025,000 shares of common stock issued and outstanding. Stock Options The grant date fair value of stock options granted during the three months ended March 31, 2016 was approximately $223,000. The fair value of the Company’s common stock was based upon the publicly quoted price on the date that the final approval of the awards was obtained. The Company does not expect to pay dividends in the foreseeable future so therefore the expected dividend yield is 0%. The expected term for stock options granted with service conditions represents the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach prescribed by the Securities and Exchange Commission’s Staff Accounting Bulletin for “plain vanilla” options. The expected term for stock options granted with performance and/or market conditions represents the estimated period estimated by management by which the performance conditions will be met. The Company obtained the risk-free interest rate from publicly available data published by the Federal Reserve. The Company uses a methodology in estimating its volatility percentage from a computation that was based on a comparison of average volatility rates of similar companies to a computation based on the standard deviation of the Company’s own underlying stock price’s daily logarithmic returns. The fair value of options granted in the three months ended March 31, 2016 was estimated using the following weighted-average assumptions: As of March 31, 2016 Exercise price $ 0.90 Expected stock price volatility 80 % Risk-free rate of interest 1.34 % Term (years) 4.6 A summary of option activity under the Company’s employee stock option plan for the three months ended March 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,050,000 $ 0.27 $ 757,000 5.1 Employee options granted 400,000 0.90 - 6.8 Outstanding as of March 31, 2016 1,450,000 $ 0.44 $ 1,271,000 5.4 Options vested and expected to vest as of March 31, 2016 1,450,000 $ 0.44 $ 1,271,000 5.4 Options vested and exercisable as of March 31, 2016 237,500 $ 0.12 $ 285,000 2.0 Estimated future stock-based compensation expense relating to unvested employee stock options is approximately $313,000 as of March 31, 2016 and will be amortized over 3.8 years. A summary of activity of options granted to non-employees for the three months ended March 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 (as reported) 2,670,000 $ 0.20 $ 2,118,000 4.0 Adjustment to stock options 150,000 0.10 134,000 2.1 Outstanding as of December 31, 2015 2,820,000 $ 0.19 $ 2,252,000 3.9 Non-employee options exercised (100,000 ) 0.11 - - Outstanding as of March 31, 2016 2,720,000 $ 0.19 $ 3,061,000 3.8 Options vested and expected to vest as of March 31, 2016 2,720,000 $ 0.19 $ 3,061,000 3.8 Options vested and exercisable as of March 31, 2016 995,000 $ 0.19 $ 1,126,000 3.9 Restricted Stock A summary of the restricted stock award activity for the three months ended March 31, 2016 is as follows: Number of Units Weighted Average Grant Date Fair Value Nonvested at December 31, 2015 650,000 $ 0.40 Vested (650,000 ) $ 0.40 Nonvested at March 31, 2016 - $ - Warrants A summary of the status of the Company’s outstanding warrants as of March 31, 2016 and changes during the three months ended March 31, 2016 is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,850,000 $ 0.31 $ 1,249,000 4.3 Issued 175,000 0.97 61,000 4.9 Outstanding as of March 31, 2016 2,025,000 $ 0.37 $ 1,921,000 4.1 Warrants exercisable as of March 31, 2016 2,025,000 $ 0.37 $ 1,921,000 4.1 Stock-based Compensation Expense Stock-based compensation expense for the three months ended March 31, 2016 and 2015 was comprised of the following (dollars in thousands): For the Three Months Ended March 31 2016 2015 Employee restricted stock awards $ 136 $ - Employee stock option awards 31 3 Non-employee option awards 460 32 Total compensation expense $ 627 $ 35

Contingencies and Commitments

Contingencies and Commitments	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Contigencies and Commitments	Note 7 – Contingencies and Commitments On March 22, 2016, the Company entered into a lease (the “Lease”) with Hudson View Building #3, LLC (the “Landlord”), for office and laboratory space located in Yonkers, New York (the “Leased Premise”). The Leased Premise consists of approximately 8,000 square feet. The Lease has a term of 87 months from the lease commencement date, which is the date upon which the Landlord has substantially completed certain interior leasehold improvements to the Leased Premise. The annual rent for the first year of the lease is approximately $208,000, increasing by 1.5% on each anniversary of the lease commencement date. In the event of a termination of the Lease following a default by the Company, the Company will be obligated to pay the sum of the rent payable for the remainder of the Lease term. The Company estimated the lease commencement date is in February, 2017. Contractual minimal lease payments are as follows (in thousands): 2016 $ - 2017 139 2018 210 2019 213 2020 217 Thereafter 744 Total $ 1,523 On February 25, 2009, the Company was granted an exclusive, worldwide, transferable, perpetual license to use certain proprietary technology for the processing of lithium for use in batteries and other fields. Commencing in October 2010, working through a third party, the Company conducted a series of tests to determine if the process worked and, based on the results, initially believed that the process produced lithium, however it did not prove to be commercially feasible and research and development efforts involving this license were abandoned. In exchange for the license, the Company had certain financial, share issuance and royalty obligations if certain sale thresholds were met. However, since contractually agreed thresholds were not met and the technology was not used, the Company negotiated an amendment and release related to this license in November 2016. Pursuant to the amendment and release, and subject to certain contingencies set forth in the amendment and release, the third party will retain two million of the three million total shares from the original license and will forfeit the remaining one million shares. The two million shares to be retained by the third party will be subject to customary transfer restrictions for restricted shares. No effect has been given to this transaction in the accompanying financial statements.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Note 8 – Subsequent Events The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The Management of the Company determined that the following reportable subsequent event(s) need to be disclosed: In April 2016, the Company entered into a private placement offering with an investor and issued 117,188 shares of the Company’s common stock and 46,875 warrants for $75,000. The warrants have a 5-year term and an exercise price of $0.97. In June 2016, the Company entered into a private placement offering with an investor and issued 100,000 shares of the Company’s common stock and 250,000 warrants for $250,000. The warrants have a 5-year term and an exercise price of $3.97. 100,000 shares issued in this offering is subjected to “price protection” for a twelve-month period. Specifically, in the event the Company issues to any person common stock or their equivalent at a lower price per share than $2.50 (the “Lower Price”), the Company shall, simultaneously with the issuance of such shares, issued that investor a number of additional common shares (the “Additional Shares”) necessary to cause the 100,000 purchased plus the Additional Shares to have a combined average cost per share equal to the Lower Price, provided that in no event shall the Additional Shares exceed 100,000 shares. The price protection featured was analyzed by the Company and the Company determined that such feature was not required to be bifurcated from the common stock and recorded as a derivative as the price protection feature is clearly and closely related to an equity host. In November 2016, the Lower Price was triggered and the Company became obligated to issue an additional 100,000 shares of common stock under the arrangement. In August 2016, the Company entered into a private placement offering with an investor and issued 40,000 shares of the Company’s common stock and 100,000 warrants for $100,000. The warrants have a 5-year term and an exercise price of $2.94. In August 2016, 221,875 warrants with a weighted average exercise price of $0.97 were exercised for cash consideration of $215,000. The investors were granted 221,875 additional warrants in August 2016 with a 5-year term and an exercise price of $2.70 per share. On November 1, 2016, the Company entered into an additional private placement offering with an investor and sold 100,000 shares of common stock and 250,000 warrants for $100,000. The warrants have a 5-year term and an exercise price of $1.16 per share. On February 25, 2009, the Company was granted an exclusive, worldwide, transferable, perpetual license to use certain proprietary technology for the processing of lithium for use in batteries and other fields by a third party. However, since contractually agreed thresholds were not met and the technology was not used, the Company negotiated an amendment and release related to this license in November 2016. Pursuant to the amendment and release, and subject to certain contingencies set forth in the amendment and release, the third party will retain two million of the three million total shares from the original license and will forfeit the remaining one million shares. The two million shares to be retained by the third party will be subject to customary transfer restrictions for restricted shares. No effect has been given to this transaction in the accompanying financial statements. On December 6, 2016, the Company cancelled 210,000 shares and exchanged 210,000 shares into 210,000 options with an exercise price of $1.08 and a 5-year term to a consultant who previously performed services prior to 2014. The consultant is related to George McKeegan, a Board member of the Company.

Significant and Critical Acco15

Significant and Critical Accounting Policies and Practices (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. For consolidated entities where the Company owns less than 100% of the subsidiary, the Company records net income (loss) attributable to non-controlling interests in its condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. The unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K filed on October 20, 2016. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value measurements, stock-based compensation, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Fair Value Measurements	Fair Value Measurements Accounts Payable and Accrued Expenses.
Cash	Cash As of March 31, 2016 and December 31, 2015, substantially all of the Company’s cash was held at major financial institutions and the balance at certain accounts may exceed the maximum amount insured by the Federal Deposit Insurance Corporation. However, the Company has not experienced losses on these accounts and management believes that the Company is not exposed to significant risks on such accounts.
Property and Equipment	Property and Equipment Office equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset, generally three years.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset over its fair value. There was no impairment of long lived assets during the quarter ended March 31, 2016.
Research and Development	Research and Development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Upfront and milestone payments due to third parties that perform research and development services on the Company’s behalf will be expensed as services are rendered or when the milestone is achieved. Research and development costs primarily consist of personnel related expenses, including salaries, benefits, travel, and other related expenses, stock-based compensation, payments made to third parties for license and milestone costs related to in-licensed products and technology, payments made to third party contract research organizations, consultants, the cost of acquiring and manufacturing clinical trial materials, and costs associated with regulatory filings, laboratory costs and other supplies. In accordance with ASC 730-10-25-1, Research and Development
Contingencies	Contingencies The Company records accruals for contingencies and legal proceedings expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated. If a loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
Stock-based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees over the requisite service period based on the estimated grant-date fair value of the awards and forfeiture rates. For stock-based compensation awards to non-employees, the Company remeasures the fair value of the non-employee awards at each reporting period prior to vesting and finally at the vesting date of the award. Changes in the estimated fair value of these non-employee awards are recognized as compensation expense in the period of change. The Company estimates the fair value of stock options grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.
Income Taxes	Income Taxes The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the largest amount of the benefit that is greater than 50% likely of being realized. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit.
Loss Per Share	Loss Per Share Basic loss per share of common stock is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share excludes the potential impact of common stock options, unvested shares of restricted stock and outstanding common stock purchase warrants because their effect would be anti-dilutive. Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at March 31, 2016 and 2015 are as follows: As of March 31, 2016 2015 Warrants to purchase common stock 2,025,000 150,000 Options to purchase common stock 4,170,000 2,670,000 Total 6,195,000 2,820,000
Non-controlling Interests	Non-Controlling Interests Non-controlling interests in consolidated entities represent the component of equity in consolidated entities held by third parties. Any change in ownership of a subsidiary while the controlling financial interest is retained is accounted for as an equity transaction between the controlling and non-controlling interests.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments

Organization and Operations (Ta

Organization and Operations (Tables)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Ownership Interest in the Subsidiary Company	Following the sale of CLC’s shares, the ownership is as follows: Stockholder Shares Percentage alpha-En Corporation 9,095,000 90.95 % Non-controlling interests 905,000 9.05 % Total: 10,000,000 100.00 %

Significant and Critical Acco17

Significant and Critical Accounting Policies and Practices (Tables)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Securities that could potentially dilute loss per share in the future that were not included in the computation of diluted loss per share at March 31, 2016 and 2015 are as follows: As of March 31, 2016 2015 Warrants to purchase common stock 2,025,000 150,000 Options to purchase common stock 4,170,000 2,670,000 Total 6,195,000 2,820,000

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	The components of property and equipment as of March 31, 2016 and December 31, 2015, at cost are (dollars in thousands): ($ in thousands) Useful Life (Years) March 31, 2016 December 31, 2015 Lab equipment 3 2 2 Office furniture and equipment 3 4 - Leasehold improvement 31 - Gross property and equipment 37 2 Less: Accumulated depreciation (1 ) - Property and equipment, net $ 36 $ 2

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2016
Schedule of Adjustment to Outstanding Shares and Options Equity	The following table provides a comparison between the previously filed numbers and the numbers after the correction as of December, 31(in thousands, except share): Previous Filings After Correction of Error 2015 2014 2015 2014 Total shares outstanding 28,649,497 26,699,497 32,235,525 30,285,525 Common stock $ 286 $ 267 $ 322 $ 303 Additional paid-in capital $ 10,741 $ 8,130 $ 10,705 $ 8,094
Schedule of Adjustment to Outstanding Shares and Options Operation	The following table provides a comparison between the previously filed numbers and the numbers after the correction for the years ended December, 31: Previous Filings After Correction of Error 2015 2014 2015 2014 Net loss $ 1,792,000 $ 47,000 $ 1,792,000 $ 47,000 Net loss per share $ (0.07 ) $ (0.00 ) $ (0.06 ) $ (0.00 ) Weighted-average shares 27,263,059 26,394,554 30,849,087 29,980,582
Schedule of Fair Value of Assumptions	The fair value of options granted in the three months ended March 31, 2016 was estimated using the following weighted-average assumptions: As of March 31, 2016 Exercise price $ 0.90 Expected stock price volatility 80 % Risk-free rate of interest 1.34 % Term (years) 4.6
Schedule of Nonvested Restricted Stock	A summary of the restricted stock award activity for the three months ended March 31, 2016 is as follows: Number of Units Weighted Average Grant Date Fair Value Nonvested at December 31, 2015 650,000 $ 0.40 Vested (650,000 ) $ 0.40 Nonvested at March 31, 2016 - $ -
Schedule of Warrants Outstanding	A summary of the status of the Company’s outstanding warrants as of March 31, 2016 and changes during the three months ended March 31, 2016 is presented below: Number of Warrants Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,850,000 $ 0.31 $ 1,249,000 4.3 Issued 175,000 0.97 61,000 4.9 Outstanding as of March 31, 2016 2,025,000 $ 0.37 $ 1,921,000 4.1 Warrants exercisable as of March 31, 2016 2,025,000 $ 0.37 $ 1,921,000 4.1
Schedule of Stock-based Compensation Expense	Stock-based compensation expense for the three months ended March 31, 2016 and 2015 was comprised of the following (dollars in thousands): For the Three Months Ended March 31 2016 2015 Employee restricted stock awards $ 136 $ - Employee stock option awards 31 3 Non-employee option awards 460 32 Total compensation expense $ 627 $ 35
Employee Stock Option [Member]
Schedule of Stock Options, Activity	A summary of option activity under the Company’s employee stock option plan for the three months ended March 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 1,050,000 $ 0.27 $ 757,000 5.1 Employee options granted 400,000 0.90 - 6.8 Outstanding as of March 31, 2016 1,450,000 $ 0.44 $ 1,271,000 5.4 Options vested and expected to vest as of March 31, 2016 1,450,000 $ 0.44 $ 1,271,000 5.4 Options vested and exercisable as of March 31, 2016 237,500 $ 0.12 $ 285,000 2.0
Non Employee Stock Option [Member]
Schedule of Stock Options, Activity	A summary of activity of options granted to non-employees for the three months ended March 31, 2016 is presented below: Number of Shares Weighted Average Exercise Price Total Intrinsic Value Weighted Average Remaining Contractual Life (in years) Outstanding as of December 31, 2015 (as reported) 2,670,000 $ 0.20 $ 2,118,000 4.0 Adjustment to stock options 150,000 0.10 134,000 2.1 Outstanding as of December 31, 2015 2,820,000 $ 0.19 $ 2,252,000 3.9 Non-employee options exercised (100,000 ) 0.11 - - Outstanding as of March 31, 2016 2,720,000 $ 0.19 $ 3,061,000 3.8 Options vested and expected to vest as of March 31, 2016 2,720,000 $ 0.19 $ 3,061,000 3.8 Options vested and exercisable as of March 31, 2016 995,000 $ 0.19 $ 1,126,000 3.9

Contigencies and Commitments (T

Contigencies and Commitments (Tables)	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contractual Minimal Lease Payments	The Company estimated the lease commencement date is in February, 2017. Contractual minimal lease payments are as follows (in thousands): 2016 $ - 2017 139 2018 210 2019 213 2020 217 Thereafter 744 Total $ 1,523

Organization and Operations (De

Organization and Operations (Details Narrative) $ in Thousands	Sep. 30, 2014USD ($)
Clean Lithium Corporation [Member]
Franchisor Disclosure [Line Items]
Capital	$ 100

Organization and Operations - S

Organization and Operations - Schedule of Ownership Interest in the Subsidiary Company (Details)	Mar. 31, 2016shares
Equity method investment, ownership percentage	100.00%
Clean Lithium Corporation [Member]
Shares, outstanding	10,000,000
Equity method investment, ownership percentage	100.00%
Alpha-En Corporation [Member] | Clean Lithium Corporation [Member]
Shares, outstanding	9,095,000
Equity method investment, ownership percentage	90.95%
Noncontrolling Interest [Member] | Clean Lithium Corporation [Member]
Shares, outstanding	905,000
Equity method investment, ownership percentage	9.05%

Going Concern and Liquidity (De

Going Concern and Liquidity (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained earnings (accumulated deficit)	$ 11,134		$ 10,169
Net loss	965	$ 62
Net cash provided by operating activities, continuing operations	$ 323	$ 95

Significant and Critical Acco24

Significant and Critical Accounting Policies and Practices (Details Narrative)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Ownership percentage	100.00%
Office equipment, useful life	3 years
Recognized tax percentage	50.00%

Significant and Critical Acco25

Significant and Critical Accounting Policies and Practices - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	6,195,000	2,820,000
Stock Option [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,170,000	2,670,000
Warrant [Member]
Franchisor Disclosure [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,025,000	150,000

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1	$ 0

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Total property and equipment	$ 37	$ 2
Less: Accumulated depreciation	(1)
Property and equipment, net	$ 36	2
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Total property and equipment	$ 2	2
Office Furniture Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Total property and equipment	$ 4
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 31

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Proceeds from related party debt	$ 92	$ 62
Advances from related parties	50
Repayments of related party debt	20
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments related to tax withholding for share-based compensation	$ 198

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Number of common shares	3,600,000
Number of stock option	75,000
Class of warrant or right, issued	2,025,000
Class of warrant or right, outstanding	2,025,000
Fair value of stock option granted | $	$ 223
Dividend yield	0.00%
Stock based compensation expense relating to unvested | $	$ 313
Amortized period	3 years 9 months 18 days
Clean Lithium Corporation [Member] | Consultant [Member]
Number of common stock issued for service	75,000
Exercise price per shares | $ / shares	$ 1
Private Placement [Member] | Investor [Member]
Number of common shares	437,501
Warrant purchase of common stock, shares	175,000
Warrant to purchase of common stock | $	$ 280
Warrant term	5 years
Exercise price of warrant | $ / shares	$ 0.97
Common Stock [Member]
Number of common shares	3,600,000
Non-Employee [Member]
Number of stock option	150,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Adjustment to Outstanding Shares and Options Equity (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Common stock	$ 334	$ 322
Additional paid-in capital	$ 11,692	$ 10,705
Previous Filings [Member]
Total shares outstanding		28,649,497	26,699,497
Common stock		$ 286	$ 267
Additional paid-in capital		$ 10,741	$ 8,130
After Correction of Error [Member]
Total shares outstanding		32,235,525	30,285,525
Common stock		$ 322	$ 303
Additional paid-in capital		$ 10,705	$ 8,094

Stockholders' Equity - Schedu31

Stockholders' Equity - Schedule of Adjustment to Outstanding Shares and Options Operation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Net loss	$ (965)	$ (62)
Net loss per share	$ (0.03)	$ 0
Weighted-average shares	32,448,987	30,285,525
Previous Filings [Member]
Net loss			$ 1,792	$ 47
Net loss per share			$ (0.07)	$ 0
Weighted-average shares			27,263,059	26,394,554
After Correction of Error [Member]
Net loss			$ 1,792	$ 47
Net loss per share			$ (0.06)	$ 0
Weighted-average shares			30,849,087	29,980,582

Stockholders' Equity - Schedu32

Stockholders' Equity - Schedule of Fair Value of Assumptions (Details)	3 Months Ended
	Mar. 31, 2016$ / shares
Equity [Abstract]
Exercise price	$ 0.09
Expected stock price volatility	80.00%
Risk-free rate of interest	1.34%
Term (years)	4 years 7 months 6 days

Stockholders' Equity - Schedu33

Stockholders' Equity - Schedule of Stock Options, Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Outstanding, Ending Balance	$ 0.09
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning Balance	1,050,000
Number of Shares, Options granted	400,000
Number of Shares, Outstanding, Ending Balance	1,450,000	1,050,000
Number of Shares, Options vested and expected to vest	1,450,000
Number of Shares, Options vested and exercisable	237,500
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 0.27
Weighted Average Exercise Price, Options granted	0.90
Weighted Average Exercise Price, Outstanding, Ending Balance	0.44	$ 0.27
Weighted Average Exercise Price, Options vested and expected to vest	0.44
Weighted Average Exercise Price, Options vested and exercisable	$ 0.12
Intrinsic Value, Outstanding, Beginning Balance	$ 757
Intrinsic Value, Options granted
Intrinsic Value, Outstanding, Ending Balance	1,271	$ 757
Intrinsic Value, Options vested and expected to vest	1,271
Intrinsic Value, Options vested and exercisable	$ 285
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	5 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Options granted	6 years 9 months 18 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	5 years 4 months 24 days
Weighted Average Remaining Contractual Life (in years), Options vested and expected to vest	5 years 4 months 24 days
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	2 years
Non Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, Beginning Balance	2,820,000	2,670,000
Number of Shares, Adjustment to stock options		150,000
Number of Shares, Option Exercised	(100,000)
Number of Shares, Outstanding, Ending Balance	2,720,000	2,820,000
Number of Shares, Options vested and expected to vest	2,720,000
Number of Shares, Options vested and exercisable	995,000
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 0.19	$ 0.2
Weighted Average Exercise Price, Adjustment to stock options		0.1
Weighted Average Exercise Price, Options Exercised	0.11
Weighted Average Exercise Price, Outstanding, Ending Balance	0.19	$ 0.19
Weighted Average Exercise Price, Options vested and expected to vest	0.19
Weighted Average Exercise Price, Options vested and exercisable	$ 0.19
Intrinsic Value, Outstanding, Beginning Balance	$ 2,252	$ 2,118
Intrinsic Value, Adjustment to stock options		134
Intrinsic Value, Options granted
Intrinsic Value, Outstanding, Ending Balance	3,061	$ 2,252
Intrinsic Value, Options vested and expected to vest	3,061
Intrinsic Value, Options vested and exercisable	$ 1,126
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	3 years 10 months 24 days	4 years
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	3 years 9 months 18 days	3 years 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Adjustment to stock options		2 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Options vested and expected to vest	3 years 9 months 18 days
Weighted Average Remaining Contractual Life (in years), Options vested and exercisable	3 years 10 months 24 days

Stockholders' Equity - Schedu34

Stockholders' Equity - Schedule of Nonvested Restricted Stock (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Units, Nonvested, Beginning Balance | shares	650,000
Number of Units, Vested | shares	(650,000)
Number of Units, Nonvested, Ending Balance | shares
Weighted Average Grant Date Fair Value, Nonvested, Beginning Balance | $ / shares	$ 0.40
Weighted Average Grant Date Fair Value, Vested | $ / shares	0.40
Weighted Average Grant Date Fair Value, Nonvested, Ending Balance | $ / shares

Stockholders' Equity - Schedu35

Stockholders' Equity - Schedule of Warrants Outstanding(Details) - Warrant [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrant, Beginning | shares	1,850,000
Number of Warrant, Issued | shares	175,000
Number of Warrant, Ending | shares	2,025,000
Number of Warrants, Warrants exercisable | shares	2,025,000
Weighted Average Exercise Price, Outstanding, Beginning Balance | $ / shares	$ 0.31
Weighted Average Exercise Price, Issued | $ / shares	0.97
Weighted Average Exercise Price, Outstanding, Ending Balance | $ / shares	0.37
Weighted Average Exercise Price, Warrants exercisable | $ / shares	$ 0.37
Intrinsic Value, Outstanding, Beginning Balance | $	$ 1,249
Intrinsic Value, Issued | $	61
Intrinsic Value, Outstanding, Ending Balance | $	1,921
Intrinsic Value, Warrants exercisable | $	$ 1,921
Weighted Average Remaining Contractual Life (in years), Outstanding, Beginning Balance	4 years 3 months 18 days
Weighted Average Remaining Contractual Life (in years), Issued	4 years 10 months 24 days
Weighted Average Remaining Contractual Life (in years), Outstanding, Ending Balance	4 years 1 month 6 days
Weighted Average Remaining Contractual Life (in years), Warrants exercisable	4 years 1 month 6 days

Stockholders' Equity - Schedu36

Stockholders' Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation	$ 627	$ 35
Employee Restricted Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation	136
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation	31	3
Non Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation	$ 460	$ 32

Contingencies and Commitments (

Contingencies and Commitments (Details Narrative) - Hudson View Building, LLC [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)a
Operating lease square feet | a	8,000
Lease term	87 months
Annual rent | $	$ 208
Increase in annual rent of lease percentage	1.50%

Contingencies and Commitments -

Contingencies and Commitments - Schedule of Contractual Minimum Lease Payments (Details) $ in Thousands	Mar. 31, 2016USD ($)
Contingencies And Commitments - Schedule Of Contractual Minimum Lease Payments Details
2,016
2,017	139
2,018	210
2,019	213
2,020	217
Thereafter	744
Total	$ 1,523

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Dec. 06, 2016	Nov. 02, 2016	Nov. 30, 2016	Aug. 31, 2016	Jun. 30, 2016	Apr. 30, 2016	Mar. 31, 2016	Nov. 01, 2016
Number of common stock shares issued							3,600,000
Subsequent Event [Member]
Number of shares cancelled during period	210,000
Number of shares exchanges during period	210,000
Subsequent Event [Member] | Stock Option [Member]
Number of shares exchanges during period	210,000
Option exercise price per share	$ 1.08
Stock option expiration term	5 years
Private Placement [Member] | Investor [Member] | Subsequent Event [Member]
Number of common stock shares issued				40,000	100,000	117,188
Shares issued price per share					$ 2.50
Private Placement [Member] | Investor [Member] | Subsequent Event [Member] | Additional Shares [Member]
Number of common stock shares issued			100,000		100,000
Private Placement [Member] | Investor [Member] | Subsequent Event [Member] | Price Protection [Member]
Number of common stock shares issued					100,000
Private Placement [Member] | Investor [Member] | Subsequent Event [Member] | Common Stock [Member]
Number of common stock shares issued				100,000	250,000	46,875
Number of warrants exercised for cash				221,875
Proceeds from warrants exercised				$ 215
Private Placement [Member] | Investor [Member] | Subsequent Event [Member] | Warrant [Member]
Proceeds from issuance of warrants				$ 100	$ 250	$ 75
Warrant, terms				5 years	5 years	5 years
Warrant, exercise price				$ 2.94	$ 3.97	$ 0.97
Warrant, weighted average exercise price				$ 0.97
Private Placement [Member] | Investor [Member] | Subsequent Event [Member] | Additional Warrant [Member]
Warrant, terms				5 years
Warrant, exercise price				$ 2.70
Number of warrants granted				221,875
Additional Private Placement [Member] | Investor [Member] | Subsequent Event [Member] | Common Stock [Member]
Number of common stock shares issued		100,000
Additional Private Placement [Member] | Investor [Member] | Subsequent Event [Member] | Warrant [Member]
Number of common stock shares issued		250,000
Proceeds from issuance of warrants		$ 100
Warrant, terms		5 years
Warrant, exercise price								$ 1.16